Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clearmind Medicine Inc. (CMND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Clearmind submits current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage psychedelic pharmaceutical biotech company listed on Nasdaq and the Frankfurt Stock Exchange.
Through these filings, investors can review press releases that are formally incorporated by reference into Clearmind’s registration statements on Form F-3 and Form S-8. Recent Form 6-K reports have attached announcements about the FDA-approved Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, including positive top-line results from the first cohort, Data and Safety Monitoring Board approval to continue the trial, and expansion of the multinational clinical-site network. Other 6-K filings describe capital-raising transactions such as registered direct offerings of common shares and pre-funded warrants, with stated uses of proceeds for operating expenses, research and development, clinical and pre-clinical testing, working capital, and general corporate purposes.
Clearmind’s filings also document corporate actions relevant to CMND stock, including a 1-for-40 reverse share split and Nasdaq notifications regarding minimum bid price and stockholders’ equity requirements. These documents outline how the company has addressed exchange listing criteria and how related matters are monitored by Nasdaq. In addition, the filings identify Clearmind’s principal executive offices in Vancouver, British Columbia, and provide details on its intellectual property-focused business model and clinical-stage status.
On Stock Titan, Clearmind’s SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the context and key points of lengthy reports, making it easier to locate information on clinical trial disclosures, financing terms, and listing compliance without reading every page in detail. Users can also review historical filings to understand how Clearmind’s development programs, capital structure, and regulatory communications have evolved over time.
Clearmind Medicine Inc., a foreign private issuer, submitted a Form 6-K to furnish a press release about its alcohol use disorder program. The release, dated November 20, 2025, states that Clearmind is accelerating an FDA-approved alcohol use disorder clinical trial by activating a fifth elite global medical site, expanding the network of locations involved in the study. The first paragraph of this press release is incorporated by reference into Clearmind’s existing registration statements on Form F-3 and Form S-8, so it becomes part of those documents for U.S. securities law purposes.
Clearmind Medicine Inc. (CMND) entered into a securities purchase agreement with investors for a registered direct offering of 10,925,000 common shares at $0.20 per share. The transaction is expected to provide aggregate gross proceeds of about $2.185 million, with closing anticipated on or about November 20, 2025, subject to customary conditions. The company plans to use the net proceeds, together with existing cash, for general corporate purposes, including operating expenses, research and development for its product candidates, working capital, potential future acquisitions and capital expenditures. The shares are being issued under an effective Form F-3 shelf registration statement via a prospectus supplement dated November 19, 2025.
Clearmind Medicine Inc. is conducting a primary offering of 10,925,000 common shares at $0.20 per share, for gross proceeds of $2,185,000 and estimated net proceeds of about $2.1 million. Shares outstanding will increase from 22,181,024 to 33,106,024, so this raise represents roughly half of the pre-offering share count. The company plans to use the cash for general corporate purposes, including operating expenses, clinical and pre-clinical development of its psychedelic-based treatments, working capital and possible acquisitions.
Clearmind is a clinical-stage pharmaceutical company developing MEAI-based therapies targeting alcohol use disorder, binge drinking, obesity and metabolic disorders, with an ongoing multinational Phase I/IIa trial. The company recently reported stockholders’ equity of $1,065,668, below Nasdaq’s $2.5 million minimum, and received a non-compliance notice. Management expects this offering, recent registered direct offerings, warrant exercises and prior note conversions to help address equity requirements, but notes that there is still a risk of Nasdaq delisting and its auditors have raised substantial doubt about the company’s ability to continue as a going concern.
Clearmind Medicine Inc. filed a Form 6-K to furnish a press release announcing positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for alcohol use disorder. The filing states that the first three paragraphs of this press release are incorporated by reference into the company’s existing shelf and equity compensation registration statements on Forms F-3 and S-8, making the clinical update part of those offerings’ disclosed information.
Clearmind Medicine Inc. furnished a Form 6-K to report a press release announcing that it filed an Israeli patent for a novel non-hallucinogenic neuroplastogen treatment for depression. The company states that the first, second and fourth paragraphs of this press release are incorporated by reference into its existing shelf registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and its equity compensation registration on Form S-8 (File No. 333-283695). This makes the key portions of the announcement part of those registration statements for U.S. securities law purposes.
Clearmind Medicine Inc. (CMND) entered into a definitive securities purchase agreement for a registered direct offering of 3,991,768 common shares and pre-funded warrants to purchase up to 1,518,000 common shares. The securities are priced at $0.25 per common share and $0.2499 per pre-funded warrant, with the warrants immediately exercisable at $0.0001 per share and exercisable on a cashless basis.
The offering is expected to close on or about November 18, 2025, with aggregate gross proceeds of approximately $1.377 million. Clearmind plans to use the net proceeds, together with existing cash, for general corporate purposes, including operating expenses, research and development such as clinical and pre-clinical testing, working capital, potential future acquisitions, and general capital expenditures. A 4.99% beneficial ownership cap limits how much of the pre-funded warrants a holder can exercise at one time.
Clearmind Medicine Inc. is offering 3,991,768 common shares and pre-funded warrants for up to 1,518,000 additional shares at $0.25 per share and $0.2499 per warrant, for gross proceeds of approximately $1.38 million before expenses. The company estimates net proceeds of about $1.3 million. Common shares outstanding were 16,671,256 as of November 14, 2025 and are expected to reach 22,181,024 if all pre-funded warrants are exercised. The cash will support general corporate purposes, including operating expenses, R&D and clinical trials.
Clearmind is a clinical-stage psychedelic medicine company developing MEAI-based treatments for alcohol use disorder, obesity, metabolic disorders and other addictive behaviors, with an ongoing multinational Phase I/IIa trial of CMND‑100 at sites including Yale and Johns Hopkins. The company recently received a Nasdaq notice for not meeting the $2.5 million minimum stockholders’ equity requirement, and its latest audited financials include substantial doubt about its ability to continue as a going concern. Management expects this offering, prior financings, warrant exercises and note conversions to help improve equity and support continued development.
Clearmind Medicine Inc. furnished a Form 6-K that attaches a press release titled “Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center.”
The first paragraph of the press release is incorporated by reference into the company’s registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).
Clearmind Medicine entered a definitive securities purchase agreement for a registered direct offering of 958,222 common shares and pre-funded warrants to purchase up to 2,984,146 common shares, priced at $0.20 per share and $0.1999 per pre-funded warrant.
The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share and may be exercised on a cashless basis, subject to a 4.99% beneficial ownership cap. Closing is expected on or about November 14, 2025, subject to customary conditions. The transaction is expected to generate approximately $0.788 million in aggregate gross proceeds. The company plans to use net proceeds, together with existing cash, for general corporate purposes, including operating expenses, R&D, working capital, potential acquisitions, and capital expenditures.
Clearmind Medicine Inc. (CMND) launched a primary offering of 958,222 common shares at $0.20 per share and pre-funded warrants to purchase up to 2,984,143 common shares at $0.1999, together with the common shares issuable upon exercise of those warrants. Each pre-funded warrant is immediately exercisable for one share at $0.0001 and remains outstanding until fully exercised, subject to 4.99% (or 9.99% at holder election) beneficial ownership limits.
The company expects gross proceeds of $788,175 before expenses and estimates net proceeds of approximately $0.78 million, to be used for general corporate purposes, including R&D and working capital. Shares outstanding were 9,601,441 as of November 12, 2025; the company states 13,543,806 would be outstanding assuming full exercise of pre-funded warrants.
CMND disclosed a Nasdaq notice of non-compliance with the $2.5 million stockholders’ equity requirement after reporting $1,065,668 of equity and has until December 18, 2025 to submit a compliance plan. Delivery of securities is expected on or about November 14, 2025, subject to customary closing conditions.